MiMedx Group, Inc.
General ticker "MDXG" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.1B (TTM average)
MiMedx Group, Inc. follows the US Stock Market performance with the rate: 7.8%.
Estimated limits based on current volatility of 2.3%: low 5.53$, high 5.80$
Factors to consider:
- Total employees count: 837 (-6.5%) as of 2024
- Top business risk factors: Failure to execute priorities, Cybersecurity threats, Market competition, Regulatory and compliance, Acquisition/divestiture risks
- Current price 25.2% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [7.04$, 12.28$]
- 2025-12-31 to 2026-12-31 estimated range: [7.24$, 12.63$]
Financial Metrics affecting the MDXG estimates:
- Positive: with PPE of 34.4 at the end of fiscal year the price was low
- Positive: 7.54 < Operating profit margin, % of 16.87
- Negative: negative Industry operating cash flow (median)
- Negative: Operating cash flow per share per price, % of 4.85 <= 6.63
- Positive: Inventory ratio change, % of 0.25 <= 0.82
- Positive: Return on assets ratio (scaled to [-100,100]) of 13.73 > 6.04
- Positive: -4.41 < Investing cash flow per share per price, % of -0.70
- Negative: Industry earnings per price (median), % of -16.21 <= 0
- Positive: Shareholder equity ratio, % of 73.17 > 64.17
- Negative: 0.01 < Interest expense per share per price, % of 0.07
- Negative: -0.18 < Industry inventory ratio change (median), % of 0
Short-term MDXG quotes
Long-term MDXG plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $267.84MM | $321.48MM | $348.88MM |
| Operating Expenses | $282.57MM | $284.36MM | $290.01MM |
| Operating Income | $-14.73MM | $37.12MM | $58.87MM |
| Non-Operating Income | $-5.02MM | $-6.48MM | $-1.57MM |
| Interest Expense | $5.02MM | $6.46MM | $1.01MM |
| R&D Expense | $12.70MM | $12.66MM | $12.34MM |
| Income(Loss) | $-19.75MM | $30.63MM | $57.29MM |
| Taxes | $0.21MM | $-36.81MM | $15.30MM |
| Other Income(Loss) | $-10.24MM | $-9.21MM | $0.42MM |
| Profit(Loss)* | $-30.20MM | $58.23MM | $42.84MM |
| Stockholders Equity | $-17.99MM | $142.72MM | $193.11MM |
| Inventory | $13.18MM | $21.02MM | $23.81MM |
| Assets | $171.43MM | $239.05MM | $263.92MM |
| Operating Cash Flow | $-17.89MM | $26.77MM | $66.20MM |
| Capital expenditure | $1.51MM | $1.99MM | $1.68MM |
| Investing Cash Flow | $-2.66MM | $-2.15MM | $-9.58MM |
| Financing Cash Flow | $-0.58MM | $-8.57MM | $-34.20MM |
| Earnings Per Share** | $-0.27 | $0.50 | $0.29 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.